Clinic
Good Samaritan Hospital Medical Center
Good Samaritan Hospital Medical Center was paid $63.30M by Medicaid between Jan 2018 and Dec 2024, across 409 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 13% of everything it billed.
33Billing provider infoGOOD SAMARITAN HOSPITAL MEDICAL CENTER
WEST ISLIP, NY 11795
WEST ISLIP, NY 11795
33aNPI1902865355assigned 03/22/2006
33bProvider typeHearing and Speech Clinic/Center
28Total paid$63.30M
24GClaims1,416,096
24DCodes billed409
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hearing and Speech Clinic/Center providers in New York
Rank by total paid#2 of 12
Median peer was paid$69K
This provider vs. median914×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,465 | $1.12M | |
| 2019 | 83,677 | $3.41M | |
| 2020 | 185,986 | $7.86M | |
| 2021 | 262,286 | $11.06M | |
| 2022 | 282,941 | $12.81M | |
| 2023 | 314,953 | $14.58M | |
| 2024incomplete | 256,788 | $12.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 13% | 64,776 | 58,869 | $7.97M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.1% | 33,895 | 32,521 | $5.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 32,838 | 31,425 | $5.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 30,019 | 28,321 | $4.43M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.4% | 21,748 | 17,809 | $4.08M |
| G0378 | Hospital observation service, per hour | 4.7% | 8,202 | 7,763 | $2.96M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 11,027 | 8,699 | $1.71M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 7,935 | 7,596 | $1.68M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 10,796 | 10,449 | $1.66M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 7,952 | 7,727 | $1.60M |
| 93975 | 2.4% | 3,352 | 3,190 | $1.54M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.4% | 8,952 | 8,511 | $1.50M |
397 more codes
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 2.3% | 3,417 | $1.43M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 1,942 | $1.33M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.5% | 1,211 | $942K |
| 80053 | Comprehensive metabolic panel | 1.4% | 54,013 | $883K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 7,100 | $710K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.0% | 1,639 | $660K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 5,258 | $634K |
| 93970 | <1% | 1,213 | $617K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,950 | $592K |
| 36415 | Collection of venous blood by venipuncture | <1% | 91,878 | $578K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 15,008 | $573K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,309 | $536K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,824 | $501K |
| 86850 | <1% | 19,550 | $463K | |
| 95782 | <1% | 513 | $430K | |
| 76770 | <1% | 1,378 | $417K | |
| 86900 | <1% | 19,761 | $413K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25,716 | $412K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,442 | $392K |
| 86901 | <1% | 19,757 | $387K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,781 | $362K |
| 96415 | <1% | 753 | $339K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,119 | $316K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,116 | $315K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,967 | $299K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,588 | $289K |
| 58558 | <1% | 231 | $267K | |
| 51701 | <1% | 957 | $262K | |
| 93458 | <1% | 145 | $241K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,758 | $218K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,484 | $215K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,095 | $191K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,947 | $183K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,245 | $176K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,605 | $173K |
| 12001 | <1% | 440 | $169K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,577 | $168K |
| 12011 | <1% | 421 | $160K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,657 | $151K |
| J3490 | Unclassified drugs | <1% | 7,118 | $146K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,287 | $145K |
| 76818 | <1% | 3,380 | $144K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,425 | $125K |
| 83880 | <1% | 4,896 | $123K | |
| 80076 | <1% | 12,706 | $122K | |
| 95816 | <1% | 913 | $107K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 891 | $106K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,471 | $105K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,969 | $104K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,507 | $102K |
| 96367 | <1% | 1,523 | $99K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 564 | $96K |
| 76830 | Ultrasound, transvaginal | <1% | 2,773 | $95K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 131 | $91K |
| 80061 | Lipid panel | <1% | 13,362 | $90K |
| 87631 | <1% | 2,110 | $90K | |
| 70496 | <1% | 387 | $90K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 123 | $88K |
| 94010 | <1% | 1,940 | $88K | |
| 97803 | <1% | 1,654 | $87K | |
| 85610 | <1% | 24,376 | $83K | |
| 64483 | <1% | 118 | $83K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 65,789 | $82K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,923 | $81K |
| 94060 | <1% | 400 | $77K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,940 | $75K |
| 76801 | <1% | 1,130 | $75K | |
| 72131 | <1% | 1,100 | $74K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 155 | $73K |
| 97802 | <1% | 1,190 | $73K | |
| 82607 | <1% | 5,992 | $71K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 973 | $70K |
| 97116 | <1% | 1,754 | $65K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,691 | $65K |
| 82728 | <1% | 5,527 | $61K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 164 | $60K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,399 | $60K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,400 | $59K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,387 | $59K |
| 84439 | <1% | 8,467 | $58K | |
| 59025 | Fetal non-stress test | <1% | 765 | $56K |
| 96040 | <1% | 1,010 | $54K | |
| 70544 | <1% | 161 | $54K | |
| 76820 | <1% | 2,447 | $53K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 59 | $50K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 189 | $50K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,671 | $50K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 659 | $50K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,966 | $49K |
| 88342 | <1% | 1,043 | $49K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,784 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,567 | $48K |
| 76821 | <1% | 1,476 | $48K | |
| 82746 | <1% | 4,186 | $48K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,073 | $47K |
| 76641 | <1% | 1,402 | $46K | |
| 84702 | <1% | 16,200 | $46K | |
| 80050 | General health panel | <1% | 1,401 | $44K |
| 81025 | <1% | 17,433 | $41K | |
| 85730 | <1% | 22,036 | $40K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 525 | $40K |
| 92592 | <1% | 364 | $38K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,396 | $37K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 852 | $37K |
| 44970 | <1% | 13 | $37K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,334 | $37K |
| 88304 | <1% | 1,842 | $36K | |
| 77336 | <1% | 95 | $35K | |
| 70498 | <1% | 343 | $34K | |
| 36223 | <1% | 25 | $33K | |
| 75574 | <1% | 193 | $32K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 122 | $32K |
| 86769 | <1% | 837 | $30K | |
| 12002 | <1% | 78 | $29K | |
| 99460 | <1% | 265 | $29K | |
| 90715 | <1% | 1,322 | $29K | |
| 97161 | <1% | 293 | $28K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,384 | $28K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,943 | $28K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 129 | $28K |
| C1769 | Guide wire | <1% | 1,053 | $28K |
| 70486 | <1% | 957 | $27K | |
| 87088 | <1% | 24,383 | $27K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 298 | $26K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,480 | $26K |
| 71250 | <1% | 290 | $25K | |
| 86480 | <1% | 495 | $25K | |
| 87486 | <1% | 1,786 | $24K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 37 | $23K |
| 88307 | <1% | 344 | $23K | |
| 87581 | <1% | 1,786 | $23K | |
| 84153 | <1% | 1,298 | $22K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 185 | $21K |
| 83540 | <1% | 4,772 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,463 | $20K |
| 84403 | <1% | 786 | $19K | |
| 58662 | <1% | 12 | $19K | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 37 | $19K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 66 | $19K |
| 92593 | <1% | 258 | $18K | |
| 95819 | <1% | 132 | $18K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,450 | $18K |
| 82784 | <1% | 1,509 | $18K | |
| 84481 | <1% | 1,937 | $17K | |
| 81003 | <1% | 34,533 | $17K | |
| 83655 | <1% | 1,323 | $17K | |
| 93971 | <1% | 307 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,820 | $16K |
| 83550 | <1% | 3,730 | $16K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 571 | $16K |
| 83921 | <1% | 736 | $15K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 94 | $15K |
| 76813 | <1% | 325 | $13K | |
| 87428 | <1% | 1,126 | $13K | |
| 70491 | <1% | 65 | $13K | |
| 29125 | <1% | 80 | $13K | |
| 86376 | <1% | 983 | $13K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 97 | $13K |
| 76870 | <1% | 262 | $13K | |
| 85027 | <1% | 8,505 | $12K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 435 | $11K |
| 82947 | <1% | 14,154 | $11K | |
| 83735 | <1% | 17,893 | $11K | |
| 83525 | <1% | 1,020 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 149 | $11K |
| 86803 | <1% | 1,418 | $11K | |
| 92570 | <1% | 203 | $10K | |
| 92526 | <1% | 76 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,391 | $10K |
| 86870 | <1% | 300 | $10K | |
| 82803 | <1% | 807 | $10K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 495 | $10K |
| 84436 | <1% | 3,286 | $10K | |
| C1874 | Stent, coated/covered, with delivery system | <1% | 14 | $10K |
| 87040 | <1% | 6,218 | $9K | |
| 86665 | <1% | 872 | $8K | |
| 88142 | <1% | 431 | $8K | |
| 86780 | <1% | 2,675 | $8K | |
| 84550 | <1% | 3,000 | $8K | |
| 84480 | <1% | 1,518 | $8K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 186 | $8K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 17 | $8K |
| 84146 | <1% | 440 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 119 | $8K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 446 | $8K |
| 83001 | <1% | 460 | $8K | |
| 77066 | Tomosynthesis, mammo | <1% | 89 | $8K |
| 99001 | <1% | 214 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,299 | $7K |
| 36430 | <1% | 17 | $7K | |
| 87077 | <1% | 3,494 | $7K | |
| 82550 | <1% | 4,450 | $7K | |
| 83090 | <1% | 392 | $7K | |
| 86800 | <1% | 550 | $7K | |
| 86318 | <1% | 1,659 | $6K | |
| 87070 | <1% | 5,172 | $6K | |
| 70547 | <1% | 27 | $6K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 28 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,752 | $6K |
| 86141 | <1% | 2,488 | $6K | |
| 96376 | <1% | 2,472 | $5K | |
| 84425 | <1% | 351 | $5K | |
| 87340 | <1% | 987 | $5K | |
| 83002 | <1% | 329 | $5K | |
| 86618 | <1% | 346 | $5K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 19 | $5K |
| 86038 | <1% | 961 | $5K | |
| 97162 | <1% | 36 | $5K | |
| 87186 | <1% | 3,388 | $5K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 163 | $5K |
| 82670 | <1% | 199 | $5K | |
| 94726 | <1% | 197 | $5K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 29 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 272 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,951 | $4K |
| 86706 | <1% | 596 | $4K | |
| 82248 | <1% | 1,216 | $4K | |
| 83615 | <1% | 1,660 | $4K | |
| 94729 | <1% | 198 | $4K | |
| 86140 | <1% | 1,098 | $4K | |
| 72128 | <1% | 238 | $4K | |
| 76937 | <1% | 24 | $4K | |
| 86664 | <1% | 437 | $4K | |
| 85007 | <1% | 5,661 | $4K | |
| 86762 | <1% | 340 | $3K | |
| 85651 | <1% | 2,644 | $3K | |
| 86663 | <1% | 438 | $3K | |
| 84630 | <1% | 383 | $3K | |
| V5266 | Battery for use in hearing device | <1% | 226 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,737 | $3K |
| 82565 | <1% | 1,042 | $3K | |
| 83690 | <1% | 14,260 | $3K | |
| 74240 | <1% | 40 | $3K | |
| 74174 | <1% | 28 | $2K | |
| 70549 | <1% | 12 | $2K | |
| 84484 | <1% | 13,791 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,251 | $2K |
| 84100 | <1% | 5,490 | $2K | |
| 86923 | <1% | 71 | $2K | |
| 82043 | <1% | 455 | $2K | |
| 86256 | <1% | 170 | $2K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 40 | $2K |
| 74018 | <1% | 1,767 | $2K | |
| 82785 | <1% | 54 | $2K | |
| 82570 | <1% | 1,169 | $2K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 61 | $2K |
| 73630 | <1% | 1,656 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 111 | $2K |
| 29515 | <1% | 12 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,179 | $2K |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 188 | $2K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12 | $2K |
| 82627 | <1% | 80 | $2K | |
| 73610 | <1% | 1,479 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 3,172 | $1K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 16 | $1K |
| 87184 | <1% | 880 | $1K | |
| 86255 | <1% | 300 | $1K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 979 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,846 | $1K |
| 82247 | <1% | 318 | $1K | |
| 99221 | <1% | 15 | $1K | |
| 73130 | <1% | 1,512 | $1K | |
| 84156 | <1% | 1,128 | $1K | |
| 93325 | <1% | 221 | $1K | |
| 76825 | <1% | 13 | $1K | |
| 81015 | <1% | 1,782 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,519 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 858 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,114 | $1K |
| 94728 | <1% | 13 | $1K | |
| 82465 | <1% | 219 | $926.42 | |
| 74019 | <1% | 2,218 | $860.21 | |
| 83970 | <1% | 26 | $855.28 | |
| 80074 | <1% | 25 | $848.32 | |
| 84255 | <1% | 37 | $832.70 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 21 | $801.65 |
| 85379 | <1% | 2,093 | $799.99 | |
| 0042T | <1% | 13 | $792.04 | |
| 82977 | <1% | 168 | $756.96 | |
| 85046 | <1% | 793 | $732.07 | |
| 92557 | <1% | 12 | $724.55 | |
| 73564 | <1% | 1,006 | $721.84 | |
| 86787 | <1% | 88 | $717.12 | |
| 83605 | <1% | 2,312 | $714.26 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 29 | $694.81 |
| 94200 | <1% | 14 | $690.80 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 1,800 | $683.41 |
| 73030 | <1% | 1,196 | $680.78 | |
| 83721 | <1% | 183 | $648.42 | |
| 84144 | <1% | 31 | $639.36 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,967 | $627.70 |
| 83021 | <1% | 37 | $609.53 | |
| 84520 | <1% | 423 | $598.72 | |
| 85384 | <1% | 1,240 | $591.77 | |
| 88173 | <1% | 28 | $577.38 | |
| 84112 | <1% | 25 | $576.60 | |
| 73562 | <1% | 276 | $565.30 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 28 | $557.99 |
| 82272 | <1% | 410 | $549.44 | |
| 87205 | <1% | 561 | $516.81 | |
| 76827 | <1% | 13 | $507.15 | |
| H0049 | Alcohol and/or drug screening | <1% | 12 | $480.25 |
| 86431 | <1% | 87 | $421.28 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,136 | $408.89 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,561 | $405.71 |
| 82077 | <1% | 3,511 | $393.47 | |
| 81001 | <1% | 243 | $355.90 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,564 | $348.44 |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 65 | $342.76 |
| 96417 | <1% | 18 | $338.85 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,817 | $338.01 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 922 | $323.42 |
| 73070 | <1% | 506 | $316.56 | |
| V5014 | Repair/modification of a hearing aid | <1% | 15 | $300.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,708 | $286.82 |
| 80143 | <1% | 2,420 | $278.84 | |
| 76642 | <1% | 13 | $271.20 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 1,706 | $268.58 |
| 73090 | <1% | 612 | $249.95 | |
| 80179 | <1% | 2,362 | $242.52 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 79 | $242.00 |
| 73110 | <1% | 735 | $240.37 | |
| 74178 | <1% | 12 | $240.02 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,148 | $239.43 |
| 84145 | <1% | 921 | $236.25 | |
| 87427 | <1% | 28 | $210.84 | |
| 85014 | <1% | 292 | $209.27 | |
| 86765 | <1% | 16 | $206.08 | |
| 86696 | <1% | 12 | $179.93 | |
| 94618 | <1% | 13 | $165.49 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 39 | $162.99 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 15 | $161.97 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 388 | $160.21 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,507 | $159.00 |
| 82340 | <1% | 32 | $153.13 | |
| C1729 | Catheter, drainage | <1% | 98 | $141.64 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 521 | $134.88 |
| 87046 | <1% | 28 | $131.05 | |
| 84479 | <1% | 149 | $130.26 | |
| 86735 | <1% | 16 | $129.04 | |
| 73590 | <1% | 539 | $125.33 | |
| 80177 | <1% | 29 | $115.82 | |
| 84132 | <1% | 376 | $109.13 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,133 | $105.74 |
| 87075 | <1% | 52 | $92.05 | |
| 87045 | <1% | 14 | $89.53 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,219 | $88.75 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 214 | $81.26 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 808 | $78.44 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,356 | $77.76 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 100 | $74.09 |
| 86592 | <1% | 146 | $70.21 | |
| 87275 | <1% | 335 | $63.79 | |
| 85008 | <1% | 201 | $60.82 | |
| C1714 | Catheter, transluminal atherectomy, directional | <1% | 13 | $58.80 |
| 84295 | <1% | 524 | $54.98 | |
| 87276 | <1% | 335 | $53.33 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 131 | $49.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,596 | $47.81 |
| 82397 | <1% | 12 | $44.80 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 445 | $41.44 |
| 82150 | <1% | 14 | $41.33 | |
| 87807 | <1% | 121 | $38.66 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 224 | $34.39 |
| 80164 | <1% | 13 | $31.34 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 233 | $28.80 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 711 | $24.34 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 459 | $24.24 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 163 | $22.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 857 | $15.51 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 183 | $14.88 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 60 | $14.02 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 393 | $13.93 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 12 | $11.66 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 49 | $8.80 |
| 73502 | <1% | 54 | $7.48 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 121 | $6.89 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 63 | $5.16 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 59 | $4.19 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 314 | $3.61 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 89 | $1.30 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 135 | $1.24 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 12 | $0.00 |
| 82435 | 0% | 102 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 75 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 24 | $0.00 |
| 73060 | 0% | 40 | $0.00 | |
| 90378 | 0% | 34 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 14 | $0.00 |
| S0166 | Injection, olanzapine, 2.5 mg | 0% | 16 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 32 | $0.00 |
| 99080 | 0% | 6,036 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 100 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 188 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 15 | $0.00 |
| 85347 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALLISON, WILLIAM (CHIEF FINANCIAL OFFICER)